The Role of Complement in Synaptic Pruning and Neurodegeneration

References

• Lo MW, Woodruff TM. Complement: bridging the innate and adaptive immune systems in sterile inflammation. J Leukoc Biol. 2020;108(1):339–351. doi:10.1002/JLB.3MIR0220-270R
   PubMed Web of Science ®Google Scholar
• Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation. 2020;17(1):354.
   PubMed Web of Science ®Google Scholar
• Tenner AJ. Complement-mediated events in Alzheimer’s disease: mechanisms and potential therapeutic targets. J Immunol. 2020;204(2):306–315. doi:10.4049/jimmunol.1901068
   Web of Science ®Google Scholar
• Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131(6):1164–1178. doi:10.1016/j.cell.2007.10.036
   PubMed Web of Science ®Google Scholar
• Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74(4):691–705. doi:10.1016/j.neuron.2012.03.026
   PubMed Web of Science ®Google Scholar
• Fatoba O, Itokazu T, Yamashita T. Complement cascade functions during brain development and neurodegeneration. FEBS J. 2021. doi:10.1111/febs.15772
   Web of Science ®Google Scholar
• Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712–716. doi:10.1126/science.aad8373
   PubMed Web of Science ®Google Scholar
• Vasek MJ, Garber C, Dorsey D, et al. A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature. 2016;534(7608):538–543. doi:10.1038/nature18283
   PubMed Web of Science ®Google Scholar
• Markarian M, Krattli RP, Baddour JD, et al. Glia-selective deletion of complement C1q prevents radiation-induced cognitive deficits and neuroinflammation. Cancer Res. 2020;81(7):1732–1744. doi:10.1158/0008-5472.CAN-20-2565.
   Web of Science ®Google Scholar
• Tenner AJ, Stevens B, Woodruff TM. New tricks for an ancient system: physiological and pathological roles of complement in the CNS. Mol Immunol. 2018;102:3–13. doi:10.1016/j.molimm.2018.06.264
   Web of Science ®Google Scholar
• Wu T, Dejanovic B, Gandham VD, et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 2019;28(8):2111–2123e2116. doi:10.1016/j.celrep.2019.07.060
   PubMed Web of Science ®Google Scholar
• Zhu H, Meissner LE, Byrnes C, Tuymetova G, Tifft CJ, Proia RL. The complement regulator susd4 influences nervous-system function and neuronal morphology in mice. iScience. 2020;23(3):100957. doi:10.1016/j.isci.2020.100957
   Web of Science ®Google Scholar
• Matsuda K. Synapse organization and modulation via C1q family proteins and their receptors in the central nervous system. Neurosci Res. 2017;116:46–53. doi:10.1016/j.neures.2016.11.004
   PubMed Web of Science ®Google Scholar
• Cong Q, Soteros BM, Wollet M, Kim JH, Sia GM. The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synapse elimination during development. Nat Neurosci. 2020;23(9):1067–1078. doi:10.1038/s41593-020-0672-0
   Web of Science ®Google Scholar
• Wang C, Yue H, Hu Z, et al. Microglia mediate forgetting via complement-dependent synaptic elimination. Science. 2020;367(6478):688–694. doi:10.1126/science.aaz2288
   PubMed Web of Science ®Google Scholar
• Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–183. doi:10.1038/nature16549
   PubMed Web of Science ®Google Scholar
• Fagan K, Crider A, Ahmed AO, Pillai A. Complement C3 expression is decreased in autism spectrum disorder subjects and contributes to behavioral deficits in rodents. Mol Neuropsychiatry. 2017;3(1):19–27. doi:10.1159/000465523
   Google Scholar
• Ziabska K, Ziemka-Nalecz M, Pawelec P, Sypecka J, Zalewska T. Aberrant complement system activation in neurological disorders. Int J Mol Sci. 2021;22(9):4675. doi:10.3390/ijms22094675
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Yalcin E, Presumey J, et al. Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice. Nat Neurosci. 2020;24(2):214–224. doi:10.1038/s41593-020-00763-8.
   Web of Science ®Google Scholar
• Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333(6048):1456–1458. doi:10.1126/science.1202529
   PubMed Web of Science ®Google Scholar
• Chu Y, Jin X, Parada I, et al. Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc Natl Acad Sci U S A. 2010;107(17):7975–7980. doi:10.1073/pnas.0913449107
   PubMed Web of Science ®Google Scholar
• Welsh Ca, Stephany CE, Sapp RW, Stevens B. Ocular dominance plasticity in binocular primary visual cortex does not require C1q. J Neurosci. 2020;40(4):769–783. doi:10.1523/JNEUROSCI.1011-19.2019
   Web of Science ®Google Scholar
• Filipello F, Morini R, Corradini I, et al. The microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity. Immunity. 2018;48(5):979–991e978. doi:10.1016/j.immuni.2018.04.016
   Web of Science ®Google Scholar
• Ding X, Wang J, Huang M, et al. Loss of microglial SIRPalpha promotes synaptic pruning in preclinical models of neurodegeneration. Nat Commun. 2021;12(1):2030. doi:10.1038/s41467-021-22301-1
   PubMed Web of Science ®Google Scholar
• Weinhard L, Di Bartolomei G, Bolasco G, et al. Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction. Nat Commun. 2018;9(1):1228. doi:10.1038/s41467-018-03566-5
   PubMed Web of Science ®Google Scholar
• Chung WS, Clarke LE, Wang GX, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504(7480):394–400. doi:10.1038/nature12776
   PubMed Web of Science ®Google Scholar
• Chung WS, Verghese PB, Chakraborty C, et al. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci U S A. 2016;113(36):10186–10191. doi:10.1073/pnas.1609896113
   PubMed Web of Science ®Google Scholar
• Shi Q, Colodner KJ, Matousek SB, et al. Complement C3-deficient mice fail to display age-related hippocampal decline. J Neurosci. 2015;35(38):13029–13042. doi:10.1523/JNEUROSCI.1698-15.2015
   PubMed Web of Science ®Google Scholar
• Vukojicic A, Delestree N, Fletcher EV, et al. The classical complement pathway mediates microglia-dependent remodeling of spinal motor circuits during development and in SMA. Cell Rep. 2019;29(10):3087–3100e3087. doi:10.1016/j.celrep.2019.11.013
   Web of Science ®Google Scholar
• Stephan AH, Madison DV, Mateos JM, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci. 2013;33(33):13460–13474. doi:10.1523/JNEUROSCI.1333-13.2013
   Web of Science ®Google Scholar
• Lui H, Zhang J, Makinson SR, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell. 2016;165(4):921–935. doi:10.1016/j.cell.2016.04.001
   PubMed Web of Science ®Google Scholar
• Figueiredo CP, Barros-Aragao FGQ, Neris RLS, et al. Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice. Nat Commun. 2019;10(1):3890. doi:10.1038/s41467-019-11866-7
   Web of Science ®Google Scholar
• Mattson MP, Partin J, Begley JG. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res. 1998;807(1–2):167–176. doi:10.1016/S0006-8993(98)00763-X
   Web of Science ®Google Scholar
• Park G, Nhan HS, Tyan SH, et al. Caspase activation and caspase-mediated cleavage of APP is associated with amyloid beta-protein-induced synapse loss in Alzheimer’s disease. Cell Rep. 2020;31(13):107839. doi:10.1016/j.celrep.2020.107839
   Web of Science ®Google Scholar
• Erturk A, Wang Y, Sheng M. Local pruning of dendrites and spines by caspase-3-dependent and proteasome-limited mechanisms. J Neurosci. 2014;34(5):1672–1688. doi:10.1523/JNEUROSCI.3121-13.2014
   PubMed Web of Science ®Google Scholar
• Gyorffy BA, Kun J, Torok G, et al. Local apoptotic-like mechanisms underlie complement-mediated synaptic pruning. Proc Natl Acad Sci U S A. 2018;115(24):6303–6308. doi:10.1073/pnas.1722613115
   Web of Science ®Google Scholar
• Gyorffy BA, Toth V, Torok G, et al. Synaptic mitochondrial dysfunction and septin accumulation are linked to complement-mediated synapse loss in an Alzheimer’s disease animal model. Cell Mol Life Sci. 2020;77(24):5243–5258. doi:10.1007/s00018-020-03468-0
   Web of Science ®Google Scholar
• Michailidou I, Willems JG, Kooi EJ, et al. Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus. Ann Neurol. 2015;77(6):1007–1026. doi:10.1002/ana.24398
   PubMed Web of Science ®Google Scholar
• Ramaglia V, Dubey M, Malpede MA, et al. Complement-associated loss of CA2 inhibitory synapses in the demyelinated hippocampus impairs memory. Acta Neuropathol. 2021:1–25. doi:10.1007/s00401-021-02338-8
   Web of Science ®Google Scholar
• Werneburg S, Jung J, Kunjamma RB, et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity. 2020;52(1):167–182e167. doi:10.1016/j.immuni.2019.12.004
   PubMed Web of Science ®Google Scholar
• Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171(3):715–727. doi:10.2353/ajpath.2007.070166
   PubMed Web of Science ®Google Scholar
• Garred P, Tenner AJ, Mollnes TE. Therapeutic targeting of the complement system: from rare diseases to pandemics. Pharmacol Rev. 2021;73(2):792–827. doi:10.1124/pharmrev.120.000072
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. Facts and figures; 2020. Available from: https://www.alz.org/alzheimers-dementia/facts-figures. Accessed September 6, 2021.
   Google Scholar
• Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2(1):a006346. doi:10.1101/cshperspect.a006346
   PubMed Web of Science ®Google Scholar
• Carpanini SM, Harwood JC, Baker E, et al. The impact of complement genes on the risk of late-onset Alzheimer’s disease. Genes (Basel). 2021;12(3):443. doi:10.3390/genes12030443
   Web of Science ®Google Scholar
• Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414–430.
   PubMed Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):383–421. doi:10.1016/S0197-4580(00)00124-X
   PubMed Web of Science ®Google Scholar
• Rivers-Auty J, Mather AE, Peters R, Lawrence CB, Brough D. Anti-inflammatories in Alzheimer’s disease-potential therapy or spurious correlate? Brain Commun. 2020;2(2):fcaa109. doi:10.1093/braincomms/fcaa109
   PubMedGoogle Scholar
• Velazquez P, Cribbs DH, Poulos TL, Tenner AJ. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer’s disease pathogenesis. Nat Med. 1997;3(1):77–79. doi:10.1038/nm0197-77
   Web of Science ®Google Scholar
• Shen Y, Lue L, Yang L, et al. Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neurosci Lett. 2001;305(3):165–168. doi:10.1016/S0304-3940(01)01842-0
   PubMed Web of Science ®Google Scholar
• Rogers J, Cooper NR, Webster S, et al. Complement activation by beta-amyloid in Alzheimer disease. ProcNatlAcadSci. 1992;89(21):10016–10020. doi:10.1073/pnas.89.21.10016
   Web of Science ®Google Scholar
• Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease. J Neurochem. 2008;106(5):2080–2092. doi:10.1111/j.1471-4159.2008.05558.x
   PubMed Web of Science ®Google Scholar
• Fonseca MI, Chu SH, Berci AM, et al. Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer’s disease. J Neuroinflammation. 2011;8(1):4. doi:10.1186/1742-2094-8-4
   Web of Science ®Google Scholar
• Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Localization and cell association of C1q in Alzheimer’s disease brain. Exp Neurol. 1996;138(1):22–32. doi:10.1006/exnr.1996.0043
   Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298(5594):789–791. doi:10.1126/science.1074069
   PubMed Web of Science ®Google Scholar
• Shi Q, Chowdhury S, Ma R, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med. 2017;9(392):392. doi:10.1126/scitranslmed.aaf6295
   Web of Science ®Google Scholar
• Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer’s disease. J Neurosci. 2004;24(29):6457–6465. doi:10.1523/JNEUROSCI.0901-04.2004
   Web of Science ®Google Scholar
• Benoit ME, Hernandez MX, Dinh ML, Benavente F, Vasquez O, Tenner AJ. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer's disease mouse models, are essential for the C1q-mediated protection against amyloid-beta neurotoxicity. J Biol Chem. 2013;288(1):654–665.
   Web of Science ®Google Scholar
• Benoit ME, Clarke EV, Morgado P, Fraser DA, Tenner AJ. Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells. J Immunol. 2012;188(11):5682–5693. doi:10.4049/jimmunol.1103760
   PubMed Web of Science ®Google Scholar
• Hernandez MX, Jiang S, Cole TA, et al. Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss. Mol Neurodegener. 2017;12(1):66. doi:10.1186/s13024-017-0210-z
   Web of Science ®Google Scholar
• Fonseca MI, Ager RR, Chu SH, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer’s disease. J Immunol. 2009;183(2):1375–1383. doi:10.4049/jimmunol.0901005
   PubMed Web of Science ®Google Scholar
• Kumar V, Lee JD, Clark RJ, Noakes PG, Taylor SM, Woodruff TM. Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice. ACS Omega. 2020;5(5):2345–2354. doi:10.1021/acsomega.9b03735
   Web of Science ®Google Scholar
• Merkel PA, Niles J, Jimenez R, et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020;2(11):662–671. doi:10.1002/acr2.11185
   PubMedGoogle Scholar
• Vergunst CE, Gerlag DM, Dinant H, et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology(Oxford). 2007;46(12):1773–1778. doi:10.1093/rheumatology/kem222
   Web of Science ®Google Scholar
• Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol. 2004;137(1):117–122. doi:10.1111/j.1365-2249.2004.02489.x
   PubMed Web of Science ®Google Scholar
• Pedersen ED, Loberg EM, Vege E, Daha MR, Maehlen J, Mollnes TE. In situ deposition of complement in human acute brain ischaemia. Scand J Immunol. 2009;69(6):555–562. doi:10.1111/j.1365-3083.2009.02253.x
   Web of Science ®Google Scholar
• Szeplaki G, Szegedi R, Hirschberg K, et al. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis. 2009;204(1):315–320. doi:10.1016/j.atherosclerosis.2008.07.044
   Web of Science ®Google Scholar
• Pavlovski D, Thundyil J, Monk PN, Wetsel RA, Taylor SM, Woodruff TM. Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J. 2012;26(9):3680–3690. doi:10.1096/fj.11-202382
   Web of Science ®Google Scholar
• Alawieh A, Elvington A, Tomlinson S. Complement in the homeostatic and ischemic brain. Front Immunol. 2015;6:417. doi:10.3389/fimmu.2015.00417
   Web of Science ®Google Scholar
• Alawieh A, Langley EF, Tomlinson S. Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice. Sci Transl Med. 2018;10(441). Available from: https://link.springer.com/article/10.1007/s00401-021-02338-8.
   Web of Science ®Google Scholar
• Alawieh A, Tomlinson S. Injury site-specific targeting of complement inhibitors for treating stroke. Immunol Rev. 2016;274(1):270–280. doi:10.1111/imr.12470
   Web of Science ®Google Scholar
• Ahmad S, Bhatia K, Kindelin A, Ducruet AF. The role of complement C3a receptor in stroke. Neuromolecular Med. 2019;21(4):467–473. doi:10.1007/s12017-019-08545-7
   Web of Science ®Google Scholar
• Brennan FH, Anderson AJ, Taylor SM, Woodruff TM, Ruitenberg MJ. Complement activation in the injured central nervous system: another dual-edged sword? J Neuroinflammation. 2012;9(1):137. doi:10.1186/1742-2094-9-137
   Web of Science ®Google Scholar
• Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008;181(11):8068–8076. doi:10.4049/jimmunol.181.11.8068
   Web of Science ®Google Scholar
• Atkinson C, Song H, Lu B, et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. JClinInvest. 2005;115(9):2444–2453.
   Web of Science ®Google Scholar
• Alawieh A, Elvington A, Zhu H, et al. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation. 2015;12(1):247. doi:10.1186/s12974-015-0464-8
   Web of Science ®Google Scholar
• Hammad A, Westacott L, Zaben M. The role of the complement system in traumatic brain injury: a review. J Neuroinflammation. 2018;15(1):24. doi:10.1186/s12974-018-1066-z
   PubMed Web of Science ®Google Scholar
• Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M. Complement activation in the human brain after traumatic head injury. J Neurotrauma. 2001;18(12):1295–1311. doi:10.1089/08977150152725605
   PubMed Web of Science ®Google Scholar
• Bellander BM, von Holst H, Fredman P, Svensson M. Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat. J Neurosurg. 1996;85(3):468–475. doi:10.3171/jns.1996.85.3.0468
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Yaffe K, Peltz CB, et al. Traumatic brain injury increases plasma astrocyte-derived exosome levels of neurotoxic complement proteins. FASEB J. 2020;34(2):3359–3366. doi:10.1096/fj.201902842R
   PubMed Web of Science ®Google Scholar
• Longhi L, Perego C, Ortolano F, et al. C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice. Crit Care Med. 2009;37(2):659–665. doi:10.1097/CCM.0b013e318195998a
   Web of Science ®Google Scholar
• Ruseva MM, Ramaglia V, Morgan BP, Harris CL. An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice. Proc Natl Acad Sci U S A. 2015;112(46):14319–14324. doi:10.1073/pnas.1513698112
   PubMed Web of Science ®Google Scholar
• Fluiter K, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J Immunol. 2014;192(5):2339–2348. doi:10.4049/jimmunol.1302793
   PubMed Web of Science ®Google Scholar
• Alawieh A, Langley EF, Weber S, Adkins D, Tomlinson S. Identifying the role of complement in triggering neuroinflammation after traumatic brain injury. J Neurosci. 2018;38(10):2519–2532. doi:10.1523/JNEUROSCI.2197-17.2018
   Web of Science ®Google Scholar
• Alawieh A, Narang A, Tomlinson S. Complementing regeneration. Oncotarget. 2015;6(26):21769–21770. doi:10.18632/oncotarget.4844
   Google Scholar
• Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol. 1996;2(4):249–258. doi:10.3109/13550289609146888
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–218. doi:10.1111/j.1750-3639.2007.00064.x
   PubMed Web of Science ®Google Scholar
• Morgan BP, Gommerman JL, Ramaglia V. An “outside-in” and “inside-out” consideration of complement in the multiple sclerosis brain: lessons from development and neurodegenerative diseases. Front Cell Neurosci. 2020;14:600656. doi:10.3389/fncel.2020.600656
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–717. doi:10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Watkins LM, Neal JW, Loveless S, et al. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. J Neuroinflammation. 2016;13(1):161. doi:10.1186/s12974-016-0611-x
   PubMed Web of Science ®Google Scholar
• Aeinehband S, Lindblom RP, Al Nimer F, et al. Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS One. 2015;10(4):e0122048. doi:10.1371/journal.pone.0122048
   PubMed Web of Science ®Google Scholar
• Ingram G, Loveless S, Howell OW, et al. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol Commun. 2014;2(1):53. doi:10.1186/2051-5960-2-53
   Web of Science ®Google Scholar
• Ingram G, Hakobyan S, Robertson NP, Morgan BP. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J Neuroimmunol. 2010;223(1–2):124–127. doi:10.1016/j.jneuroim.2010.03.014
   Web of Science ®Google Scholar
• Ingram G, Hakobyan S, Hirst CL, et al. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult Scler. 2012;18(10):1401–1411. doi:10.1177/1352458512438238
   PubMed Web of Science ®Google Scholar
• Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008;63(1):16–25. doi:10.1002/ana.21311
   PubMed Web of Science ®Google Scholar
• Michailidou I, Jongejan A, Vreijling JP, et al. Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. Acta Neuropathol Commun. 2018;6(1):36. doi:10.1186/s40478-018-0536-y
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625. doi:10.1056/NEJMoa1900866
   PubMed Web of Science ®Google Scholar
• Hammond JW, Bellizzi MJ, Ware C, et al. Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. Brain Behav Immun. 2020;87:739–750. doi:10.1016/j.bbi.2020.03.004
   PubMed Web of Science ®Google Scholar
• Stupp R, Mayer M, Kann R, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre Phase II trial. Lancet Oncol. 2009;10(8):785–793. doi:10.1016/S1470-2045(09)70172-X
   PubMed Web of Science ®Google Scholar
• Dietrich J, Gondi V, Mehta M. Delayed complications of cranial irradiation; 2020. Available from: https://www.uptodate.com/contents/delayed-complications-of-cranial-irradiation. Accessed September 6, 2021.
   Google Scholar
• Lawrie TA, Gillespie D, Dowswell T, et al. Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. Cochrane Database Syst Rev. 2019;8:CD013047.
   PubMed Web of Science ®Google Scholar
• Merchant TE, Kiehna EN, Kun LE, et al. Phase II trial of conformal radiation therapy for pediatric patients with craniopharyngioma and correlation of surgical factors and radiation dosimetry with change in cognitive function. J Neurosurg. 2006;104(2 Suppl):94–102.
   PubMed Web of Science ®Google Scholar
• Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol. 1992;10(9):1390–1396. doi:10.1200/JCO.1992.10.9.1390
   PubMed Web of Science ®Google Scholar
• Merchant TE, Kiehna EN, Li C, et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys. 2006;65(1):210–221. doi:10.1016/j.ijrobp.2005.10.038
   PubMed Web of Science ®Google Scholar
• Acharya MM, Green KN, Allen BD, et al. Elimination of microglia improves cognitive function following cranial irradiation. Sci Rep. 2016;6(1):31545. doi:10.1038/srep31545
   PubMed Web of Science ®Google Scholar
• Parihar VK, Acharya MM, Roa DE, Bosch O, Christie LA, Limoli CL. Defining functional changes in the brain caused by trageted stereotaxic radiosurgery. Transl Cancer Res. 2014;3(2):124–137.
   PubMed Web of Science ®Google Scholar
• Acharya MM, Baulch JE, Lusardi TA, et al. Adenosine kinase inhibition protects against cranial radiation-induced cognitive dysfunction. Front Mol Neurosci. 2016;9:42. doi:10.3389/fnmol.2016.00042
   PubMed Web of Science ®Google Scholar
• Markarian M, Krattli RP, Alikhani L, et al. Glia-selective deletion of complement C1q prevents cranial radiation-induce cognitive impairments and neuroinflammation. Cancer Res. 2021;81(7):1732-1744. doi:10.1158/0008-5472.CAN-20-2565
   Web of Science ®Google Scholar
• Montay-Gruel P, Acharya MM, Petersson K, et al. Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species. Proc Natl Acad Sci U S A. 2019;116(22):10943–10951. doi:10.1073/pnas.1901777116
   PubMed Web of Science ®Google Scholar
• Bell B, Lin JJ, Seidenberg M, Hermann B. The neurobiology of cognitive disorders in temporal lobe epilepsy. Nat Rev Neurol. 2011;7(3):154–164. doi:10.1038/nrneurol.2011.3
   Web of Science ®Google Scholar
• Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer's disease. Arch Neurol. 2009;66(4):435–440. doi:10.1001/archneurol.2009.15
   PubMedGoogle Scholar
• Rusina R, Ridzon P, Kulist’ak P, et al. Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A Prospective Study. Eur J Neurol. 2010;17(1):23–30. doi:10.1111/j.1468-1331.2009.02717.x
   PubMed Web of Science ®Google Scholar
• Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson's disease. J Neurol Sci. 2010;289(1–2):18–22. doi:10.1016/j.jns.2009.08.034
   PubMed Web of Science ®Google Scholar
• Fonseca MI, Chu SH, Hernandez MX, et al. Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J Neuroinflammation. 2017;14(1):48. doi:10.1186/s12974-017-0814-9
   PubMed Web of Science ®Google Scholar
• Guttenplan KA, Weigel MK, Adler DI, et al. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat Commun. 2020;11(1):3753. doi:10.1038/s41467-020-17514-9
   PubMed Web of Science ®Google Scholar
• Hinkle JJ, Olschowka JA, Love TM, Williams JP, O’Banion MK. Cranial irradiation mediated spine loss is sex-specific and complement receptor-3 dependent in male mice. Sci Rep. 2019;9(1):18899. doi:10.1038/s41598-019-55366-6
   PubMed Web of Science ®Google Scholar
• Kalm M, Andreasson U, Bjork-Eriksson T, et al. C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning. Oncotarget. 2016;7(15):19382–19394. doi:10.18632/oncotarget.8400
   PubMedGoogle Scholar
• DeCordova S, Abdelgany A, Murugaiah V, et al. Secretion of functionally active complement factor H related protein 5 (FHR5) by primary tumour cells derived from Glioblastoma Multiforme patients. Immunobiology. 2019;224(5):625–631. doi:10.1016/j.imbio.2019.07.006
   Web of Science ®Google Scholar
• Fornvik K, Ahlstedt J, Osther K, Salford LG, Redebrandt HN. Anti-C1-inactivator treatment of glioblastoma. Oncotarget. 2018;9(100):37421–37428. doi:10.18632/oncotarget.26456
   Google Scholar
• Bulla R, Tripodo C, Rami D, et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. 2016;7(1):10346. doi:10.1038/ncomms10346
   PubMed Web of Science ®Google Scholar
• Mangogna A, Agostinis C, Bonazza D, et al. Is the complement protein C1q a pro- or anti-tumorigenic factor? Bioinformatics analysis involving human carcinomas. Front Immunol. 2019;10:865. doi:10.3389/fimmu.2019.00865
   PubMed Web of Science ®Google Scholar
• Bouwens TA, Trouw LA, Veerhuis R, Dirven CM, Lamfers ML, Al-Khawaja H. Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. J Neuroimmunol. 2015;278:271–276. doi:10.1016/j.jneuroim.2014.11.016
   Web of Science ®Google Scholar
• Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2013;228(7):1404–1412. doi:10.1002/jcp.24260
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang C, Zhang Z, et al. Specific clinical and immune features of CD68 in glioma via 1024 samples. Cancer Manag Res. 2018;10:6409–6419. doi:10.2147/CMAR.S183293
   PubMed Web of Science ®Google Scholar
• Mangogna A, Belmonte B, Agostinis C, et al. Prognostic implications of the complement protein C1q in gliomas. Front Immunol. 2019;10:2366. doi:10.3389/fimmu.2019.02366
   PubMed Web of Science ®Google Scholar
• Nunez-Cruz S, Gimotty PA, Guerra MW, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia. 2012;14(11):994–1004. doi:10.1593/neo.121262
   Web of Science ®Google Scholar
• Olcina MM, Melemenidis S, Nambiar DK, et al. Targeting C5aR1 increases the therapeutic window of radiotherapy. bioRxiv. 2020;2020. Available from: https://www.biorxiv.org/content/10.1101/2020.10.27.358036v2.full#:~:text=Here%20we%20show%20that%20targeting,thereby%20increasing%20the%20therapeutic%20window.
   Google Scholar
• de Erausquin GA, Snyder H, Carrillo M, et al. The chronic neuropsychiatric sequelae of COVID-19: the need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2021;17(6):1056–1065. doi:10.1002/alz.12255
   PubMed Web of Science ®Google Scholar
• Yang AC, Kern F, Losada PM, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595(7868):565–571. doi:10.1038/s41586-021-03710-0
   PubMed Web of Science ®Google Scholar
• Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiatry. 2021;78(6):682–683. doi:10.1001/jamapsychiatry.2021.0500
   PubMed Web of Science ®Google Scholar
• Holter JC, Pischke SE, de Boer E, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. 2020;117(40):25018–25025. doi:10.1073/pnas.2010540117
   PubMed Web of Science ®Google Scholar
• Zelek WM, Menzies GE, Brancale A, Stockinger B, Morgan BP. Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology. 2020;161(2):103–113. doi:10.1111/imm.13228
   Web of Science ®Google Scholar
• Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215:108450. doi:10.1016/j.clim.2020.108450
   PubMed Web of Science ®Google Scholar
• Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL napoli 2 nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–4047.
   PubMed Web of Science ®Google Scholar
• Gavriilaki M, Kimiskidis VK, Gavriilaki E. Precision medicine in neurology: the inspirational paradigm of complement therapeutics. Pharmaceuticals. 2020;13(11):341. doi:10.3390/ph13110341
   Web of Science ®Google Scholar
• Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341–352. doi:10.1016/j.molimm.2019.07.030
   PubMed Web of Science ®Google Scholar
• Wouters Y, Jaspers T, De Strooper B, Dewilde M. Identification and in vivo characterization of a brain-penetrating nanobody. Fluids Barriers CNS. 2020;17(1):62. doi:10.1186/s12987-020-00226-z
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019;18(9):707–729. doi:10.1038/s41573-019-0031-6
   PubMed Web of Science ®Google Scholar
• Peterson SL, Anderson AJ. Complement and spinal cord injury: traditional and non-traditional aspects of complement cascade function in the injured spinal cord microenvironment. Exp Neurol. 2014;258:35–47. doi:10.1016/j.expneurol.2014.04.028
   Web of Science ®Google Scholar
• Peterson SL, Nguyen HX, Mendez OA, Anderson AJ. Complement protein C1q modulates neurite outgrowth in vitro and spinal cord axon regeneration in vivo. J Neurosci. 2015;35(10):4332–4349. doi:10.1523/JNEUROSCI.4473-12.2015
   PubMed Web of Science ®Google Scholar
• Benavente F, Piltti KM, Hooshmand MJ, et al. Novel C1q receptor-mediated signaling controls neural stem cell behavior and neurorepair. Elife. 2020;9:e55732. doi:10.7554/eLife.55732
   Web of Science ®Google Scholar
• Yuzaki M. The C1q complement family of synaptic organizers: not just complementary. Curr Opin Neurobiol. 2017;45:9–15. doi:10.1016/j.conb.2017.02.002
   PubMed Web of Science ®Google Scholar
• Suzuki K, Elegheert J, Song I, et al. A synthetic synaptic organizer protein restores glutamatergic neuronal circuits. Science. 2020;369:6507. doi:10.1126/science.abb4853
   Web of Science ®Google Scholar